Trial reportEuropean journal of heart failure2020
Serum potassium in the PARADIGM-HF trial.
Trial report in European journal of heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- The Efficacy and Safety of Patiromer for Heart Failure Patients: A Systematic Review and Meta-Analysis.Cardiovascular drugs and therapy · 2024Pooled it
- Potassium levels and the risk of all-cause and cardiovascular mortality among patients with cardiovascular diseases: a meta-analysis of cohort studies.Nutrition journal · 2024Pooled it
- Impacts of Sacubitril-Valsartan versus Valsartan on Left Ventricular Remodeling and Cardiac Function in Patients with Ischemic Heart Failure and Reduced Ejection Fraction: A Randomized Double-blinded Controlled Trial.Cardiovascular & hematological disorders drug targets · 2026Trial
- Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.European heart journal · 2022Trial
- Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.European journal of heart failure · 2022Trial
- Zilebesiran in Hypertension: Reversibility, Acute Illness, and Therapeutic Flexibility.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Synergistic Effects of Normal-Range Serum Sodium and Potassium on Mortality: The Modifying Role of Inflammation From a NHANES Cohort Analysis.Chronic diseases and translational medicine · 2026Article
- Hyperkalemia management in heart failure and chronic kidney disease: a Spanish cost-effectiveness analysis of patiromer informed by the integrated DIAMOND trial and real-world evidence.BMC health services research · 2026Article
- Observational
- Determination of serum concentrations of canrenone (active metabolite of spironolactone) in patients with heart failure with reduced ejection fraction: a cross-sectional study.Pharmacological reports : PR · 2025Article
- Hyperkalemia in Heart Failure with Reduced Ejection Fraction Patients Treated with Sacubitril/Valsartan: Experience from a Tertiary Cardiac Center in Riyadh, Saudi Arabia.Clinics and practice · 2025Article
- Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations).Heart failure reviews · 2025Review
- EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease and Heart Failure.Cardiorenal medicine · 2025Review
- Cardiovascular Benefits of Spironolactone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from a Win Ratio Analysis of the TOPCAT Trial.Cardiac failure review · 2025Article
- To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.Frontiers in cardiovascular medicine · 2025Review
- Pharmacological Therapy of HFrEF in 2025: Navigating New Advances and Old Unmet Needs in An Eternal Balance Between Progress and Perplexities.Cardiac failure review · 2025Review
- Association of potassium disorders with the mode of death and etiology in patients with chronic heart failure: the INCOR-HF study.Scientific reports · 2024Article
- Sacubitril-Valsartan in Patients Requiring Hemodialysis.JAMA network open · 2024Article
- Relationship between Baseline Serum Potassium and 1-Year Readmission in Pediatric Patients with Heart Failure: A Retrospective Cohort Study.Children (Basel, Switzerland) · 2024Article
- Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists.Diabetologia · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 5 countries.
Funding
Abstract
aimsThe associations between potassium level and outcomes, the effect of sacubitril-valsartan on potassium level, and whether potassium level modified the effect of sacubitril-valsartan in patients with heart failure and a reduced ejection fraction were studied in PARADIGM-HF. Several outcomes, including cardiovascular death, sudden death, pump failure death, non-cardiovascular death and heart failure hospitalization, were examined. METHODS AND
resultsA total of 8399 patients were randomized to either enalapril or sacubitril-valsartan. Potassium level at randomization and follow-up was examined as a continuous and categorical variable (≤3.5, 3.6-4.0, 4.1-4.9, 5.0-5.4 and ≥5.5 mmol/L) in various statistical models. Hyperkalaemia was defined as K
conclusionsAlthough both higher and lower potassium levels were independent predictors of cardiovascular death, potassium abnormalities may mainly be markers rather than mediators of risk for death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.